Reuters is leveraging its global expertise in health and the pharmaceutical industry – and its deep sourcing with governments and health authorities worldwide – to bring readers and clients an unparalleled view of the fight against COVID-19. Scientists, governments and drugmakers have mounted a historic race to understand the new coronavirus and identify vaccines and treatments that will save lives worldwide. Reuters has been there at every turn, telling the inside story of that campaign and providing exclusive reporting on the advances and setbacks along the way.
UNPARALLELED INSIGHT

- COVID opens new doors for China’s gene giant
- ‘Vaccine nationalism’: Is it every country for itself?
- The U.S. has more COVID-19 testing than most. So why is it falling so short?
- Why COVID-19 is killing U.S. diabetes patients at alarming rates
- Bolsonaro bets ‘miraculous cure’ for COVID-19 can save Brazil - and his life
- Scientists hunt pandemic hotspots in race to test vaccines
- FDA’s lax rules on coronavirus blood tests open U.S. market to dubious vendors
- As virus advances, doctors rethink rush to ventilate
- How Korea trounced U.S. in race to test people for coronavirus

EXCLUSIVE NEWS

- EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags
- U.S. plans massive coronavirus vaccine testing effort to meet year-end deadline
- A quarter of Americans are hesitant about a coronavirus vaccine
- Novavax execs could get big payday even if vaccine fails
- Fauci bullish on prospects for U.S. vaccine, not worried about China winning race
- Moderna spars with U.S. scientists over COVID-19 vaccine trials
- J&J says in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine
- Russia, despite theft allegations, hails deal to make UK-developed COVID-19 vaccine
- Vaccine alliance finds manufacturing capacity for 4 billion doses of coronavirus vaccines
- EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal
- Lilly COVID-19 treatment could be authorized for use as soon as September
- Europe to accelerate trials of gene-engineered COVID-19 vaccines
- Lonza sets new goal to make Moderna COVID-19 vaccine ingredients
- European Investment Bank to raise COVID-19 fund to 2 billion euros
- Fearing shortages, EU may deploy emergency funds in COVID-19 vaccine race
- Pressed by Trump, U.S. pushed unproven coronavirus treatment guidance
THE BIG PICTURE

EYE ON THE STORY

• Long way to go, but WHO welcomes vaccine news
• Pharma execs forecast aggressive vaccine timeline
• COVID-19 vaccine’s human trials show promise
• Africa’s first coronavirus vaccine trial begins
• Coronavirus vaccine possible in early 2021
• China would make a coronavirus vaccine a “global public product”
• Pfizer, BioNTech get vaccine ‘fast track’ from FDA

TRUSTED VIEWS

Reuters Breakingviews offers unmatched, agenda-setting commentary. Highlights include:
• Coronavirus vaccine hopes inflate bubble
• Corona Capital: Flying high
• Gilead gives glimpse into feverish drug market
• Moderna puts stock sale opportunism to test
• Vaccine victory would be half cure for economy

HOW TO ACCESS

• In Eikon, search COVID and NEWS1 in the News Monitor.
• Explore the economic impact of the coronavirus pandemic using the COVID-19 Macro Vitals Eikon app. Search MACROV in Eikon.
• Access the latest stories online at reuters.com.
• Get agenda-setting commentary from Reuters Breakingviews.
• View COVID Science, a regularly-updated curated collection of scientific findings.

• Publishers can access multimedia content from Reuters Connect.
• Access market-leading events, reports and expert-driven content for the pharma sector, and more, from Reuters Events.
• Check out the #AskReuters Twitter chat series on coronavirus.
• Follow Reuters on Twitter and Facebook.

FOLLOW ALONG WITH REUTERS

Unlock more unrivaled coverage from Reuters and discover the latest editions of Reuters: The Big Picture.